Fusion Antibodies
Fusion was established in 2001 as a spin-out from Queen’s University Belfast. The Company has won a host of awards for its leading-edge technology platform FET (Fusion Expression Technology) which accelerates the validation of targets from DNA sequence through to recombinant protein expression. Fusion generates target specific antibodies from protein antigens with the capability, to modify their characteristics to increase efficacy.
These technologies support Fusion’s own therapeutic and diagnostic R&D, and are also offered as a service to pharmaceutical, biopharmaceutical and academic researchers, allowing them to achieve their goals faster and more cost effectively.
Contact Details
Crescent Contact : Colin Walsh
Springbank Industrial estate
Pembroke Loop road
Dunmurry
Belfast, BT17 0QL
Northern Ireland
http://www.fusionantibodies.com
Jim Johnston CEO Fusion Antibodies
Fusion was established in 2001 as a spin-out from Queen’s University Belfast.
The Company has won a host of awards for its leading-edge technology platform FET (Fusion Expression Technology) which accelerates the validation of targets from DNA sequence through to recombinant protein expression.
Fusion generates target specific antibodies from protein antigens with the capability, to modify their characteristics to increase efficacy.
Crescent Capital NI Ltd is authorised and regulated by the Financial Services Authority
Crescent Capital NI Ltd is a member of the EVCA